Merus
Price & Volume
Stats
See more52W Range | $37.77-$61.61 |
Market Cap | $3.2B |
Shares Short | 7M |
Financials
See moreRevenue (12 Mos) | $35.9M |
Revenue Growth (YoY) | 6.7% |
Gross Profit (12 Mos) | -$110.1M |
Diluted EPS | -$4.03 |
News
See moreYahoo Finance • 4 days ago
Petosemtamab erhält von der FDA in den USA die Breakthrough Therapy Designation für die Erstlinienbehandlung von PD-L1-positiven Kopf-Hals-Plattenepithelkarzinomen
Yahoo Finance • 5 days ago
Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinoma
Yahoo Finance • 10 days ago
Merus wird beim 2025 Virtual Oncology Leadership Summit von Citi eine Präsentation halten
Yahoo Finance • 18 days ago
New England Journal of Medicine Publishes: Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer
About
CEO | Dr. Sven Ante Lundberg M.D. |
Address | Uppsalalaan 17, Utrecht, Netherlands, 3584 CT |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 172 |
